The common treatment regime of Myeloma involves several disease stages and different molecules. These molecules are, at times, substitutes or competing and at others complementary because caregivers may combine for treatment even competing molecules. In spite of this reality at least in Israel, the state’s Basket Committee, which prioritizes new technologies for entitlement, attempts to consider the individual molecules for its cost-effectiveness and other consideration. The committee’s approach is thus erroneous and sub-optimal. A holistic approach whereby all pertinent molecules are considered as a whole would help rationalize individual molecule adoption and treatment decisions. This approach is by-passed routinely for three main reasons. First, competition amongst pharmaceutical companies prevents cooperation although they are often implicit ‘collaborators’ in the treatment. Second, the lack of an agreed and ‘binding’ treatment protocol by the profession. Finally, it often pays the treatment, the state may refrain from imposing a ‘financially optimal’ treatment protocol, to uphold competition, on the one hand, and preserve ‘clinical freedom’, on the other. This paper presents a holistic cost model for the treatment of Myeloma in Israel based on 2016 – 2018 data. The stock-flow model comprises a five-year four-stage consensus treatment regime. It includes for each year the following patient variables: the number of patients (prevalence): (1) the number of new patients (incidence), (2) high-risk and low-risk patients, (3) patients qualifying for transplantation and those who do not, (4) patients in active treatment and (5) those in progression free survival. The molecules considered are of the following families: (a) Immunomodulators, (b) Protesase inhibitors, (c) Monoclonal antibodies, and (d) more traditional chemotherapy. The model, which can be modified for other conditions and treatments, provides the optimal annual treatment cost of the ‘stock’ of patients, and those of s single average patient over five years, for better decision making.